Market Overview

Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys

Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys

Sarepta Therapeutics Inc (NASDAQ: SRPT) presented encouraging long-term cardiac and pulmonary data at the MDA Scientific Conference. The data could provide “additional support for the clinical benefit from Exondys 51 treatment,” SunTrust Robinson Humphrey’s Edward Nash said in a report.

Nash upgraded the stock from Hold to Buy, while maintaining the price target at $45. He commented, “We are more bullish on payer coverage and market adoption of Exondys 51.”

Data To Support Payer Education

Management’s guidance implies that as high as 79 percent of insurance plans are pending policy decisions.

The analyst expressed optimism regarding the cardiac and pulmonary function data providing support to Sarepta’s efforts in payer education. He explained that this would be a more important measure than loss of ambulation for physicians to determine the clinical benefit of Exondys 51, since the deteriorating of cardiac and pulmonary function has a more severe impact on patient’s immediate quality of life.

Related Link: Payor Re-Evaluation On Exondys Positive For Sarepta

US Launch Expectations

“The initial trend of U.S. launch is encouraging,” Nash commented.

Management suggested the tier 1 and tier 2 DMD [Duchenne Muscular Dystrophy] centers account for 80 percent of the entire DMD market. Management also indicated that all these centers, with the exception of one tier 2 center, had submitted a start form.

Management had guided to net revenue of $13-$15 million for Q1 2017 and of at least $80 million for FY2017.

Latest Ratings for SRPT

Apr 2020Morgan StanleyMaintainsOverweight
Mar 2020MizuhoInitiates Coverage OnBuy
Feb 2020JP MorganMaintainsOverweight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!

Posted-In: Edward Nash Exondys 51Analyst Color Long Ideas Upgrades Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

NGMBMO CapitalInitiates Coverage On30.0
RFPRBC CapitalDowngrades2.5
RYAMRBC CapitalDowngrades3.0
SMCILoop CapitalInitiates Coverage On35.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at